Low doses of insulin-like growth factor-I induce mitochondrial protection in aging rats.
Serum IGF-I levels decline with age. We have recently reported that in aging rats the exogenous administration of IGF-I restores IGF-I circulating levels and age related-changes, improving glucose and lipid metabolisms, increasing testosterone levels and serum total antioxidant capability, and reducing oxidative damage in the brain and liver associated with a normalization of antioxidant enzyme activities. Understanding that mitochondria are one of the most important cellular targets of IGF-I, the aims of this study were to characterize mitochondrial dysfunction and study the effect of IGF-I therapy on mitochondria, leading to cellular protection in the following experimental groups: young controls, untreated old rats, and aging rats treated with IGF-I. Compared with young controls, untreated aging rats showed an increase of oxidative damage in isolated mitochondria with a mitochondrial dysfunction characterized by: depletion of membrane potential with increased proton leak rates and intramitochondrial free radical production, and a significant reduction of ATPase and complex IV activities. In addition, mitochondrial respiration from untreated aging rats was atractyloside insensitive, suggesting that the adenine nucleotide translocator was uncoupled. The adenine nucleotide translocator has been shown to be one of the most sensitive locations for pore opening. Accordingly, untreated aging rats showed a significant overexpression of the active fragment of caspases 3 and 9. IGF-I therapy corrected these parameters of mitochondrial dysfunction and reduced caspase activation. In conclusion, these results show that the cytoprotective effect of IGF-I is closely related to a mitochondrial protection, leading to reduce free radical production, oxidative damage, and apoptosis, and to increased ATP production.
Puche
Juan E
JE
Department of Medical Physiology, School of Medicine, University CEU-Universidad San Pablo, Boadilla del Monte, 28668, Madrid, Spain.
García-Fernández
María
M
Muntané
Jordi
J
Rioja
José
J
González-Barón
Salvador
S
Castilla Cortazar
Inma
I
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000375:Aging / Q000187:drug effects*; D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D020169:Caspases / Q000378:metabolism; D019610:Cytoprotection / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D003576:Electron Transport Complex IV / Q000378:metabolism; D022781:Hepatocytes / Q000187:drug effects; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology*; D008297:Male; D020782:Matrix Metalloproteinases / Q000378:metabolism; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D018384:Oxidative Stress / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects; D017494:Proton Pumps / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D000975:Antioxidants; D017494:Proton Pumps; D007334:Insulin-Like Growth Factor I; D003576:Electron Transport Complex IV; D020169:Caspases; D020782:Matrix Metalloproteinases; D000251:Adenosine Triphosphatases